Small biotech campaigns for biogenerics law
The small biotech Insmed has been lobbying for new legislation that would clear a regulatory pathway for biosimilars. The Richmond, VA-based company wants to develop a portfolio of follow-ons and CEO Geoffrey Allan has been patiently educating lawmakers on the intricacies of biologics and how biosimilars could be made safely and inexpensively. Insmed has already mounted a small trial for its version of Amgen's Neupogen, which is on just about everyone's list of biologics most likely to face competition first.
Of course, Insmed's argument is diametrically opposed to the Biotechnology Industry Organization's, which has been campaigning for years to make sure any biosimilar law would require extensive trials after a prolonged period of exclusivity.
- read the report in the Washington Post
Related Articles:
Live from BIO: For Biotechs, a bright future with challenges
Biotech's next big opportunity: Follow-ons?
Budget has mandate for biogeneric approvals
Waiting game continues for biogenerics
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
